ESMO 2017 | Eagerly anticipated results of the FLAURA trial

Sanjay Popat, BSc MBBS FRCP PhD, from the Royal Marsden Hospital, London, UK, discusses the The FLAURA study (NCT02296125) at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. The FLAURA study investigated patients with EGFR mutant non-small cell lung cancer. Patients were randomised to either gefitinib or erlotinib, the primary endpoint of the trial being progression free survival. The results of this trial were positive, and vey eagerly awaited.